Biogen Inc. shares slipped in the extended session Monday following a report, later confirmed by Biogen, that the biotech company will appoint a new chief executive. Biogen shares declined 0.6% to $277 after hours. Biogen said Chief Commercial Officer Michel Vounatsos will become CEO on Jan. 6, succeeding George Scangos, who has been CEO since 2010.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.